NCT06576765View on ClinicalTrials.gov

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

November 8, 2024

Study Completion Date

November 8, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

AZD0780

Dose 1

Trial Locations (3)

32809

Research Site, Orlando

33014

Research Site, Hialeah

78215

Research Site, San Antonio

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY